Skip to main content
SpringerLink
Log in

Treatment of Myeloproliferative Neoplasms

  • Chapter
  • First Online:
Neoplastic Hematopathology

Part of the book series: Contemporary Hematology ((CH))

  • 2164 Accesses

Abstract/Scope of Chapter

The treatment of chronic myeloproliferative neoplasms, including chronic myelogenous leukemia, polycythemia vera, primary myelofibrosis, and essential thrombocythemia are summarized. The indications for supportive care versus chemotherapy versus targeted (kinase inhibitor) therapy and stem cell transplantation are compared.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 229.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 299.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 299.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Tefferi A, Thiele J, Orazi A, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.

    Article  PubMed  CAS  Google Scholar 

  2. Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood 2008;111:4022-8.

    Article  PubMed  CAS  Google Scholar 

  3. Spivak JL. Polycythemia vera and other myeloproliferative diseases. In: Harrison’s principles of internal medicine. New York: McGraw-Hill, 2005:626-31.

    Google Scholar 

  4. Tefferi A. Polycythemia vera: a comprehensive review and clinical recommendations. Mayo Clin Proc 2003;78:174-94.

    Article  PubMed  Google Scholar 

  5. Andrieux J, Demory JL, Caulier MT, et al. Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 2003;140:118-23.

    Article  PubMed  CAS  Google Scholar 

  6. Sanchez S, Ewton A. Essential thrombocythemia: a review of diagnostic and pathologic features. Arch Pathol Lab Med 2006;130:1144-50.

    PubMed  Google Scholar 

  7. Vannucchi AM, Antonioli E, Guglielmelli P, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. Blood 2008;112:844-7.

    Article  PubMed  CAS  Google Scholar 

  8. Tefferi A. Myelofibrosis with myeloid metaplasia. N Engl J Med 2000;342:1255-65.

    Article  PubMed  CAS  Google Scholar 

  9. Tefferi A, Sirhan S, Sun Y, et al. Oligonucleotide array CGH studies in myeloproliferative neoplasms: Comparison with JAK2V617F mutational status and conventional chromosome analysis. Leuk Res 2009;33:662-4.

    Article  PubMed  CAS  Google Scholar 

  10. Passamonti F, Malabarba L, Orlandi E, et al. Polycythemia vera in young patients: a study on the long-term risk of thrombosis, myelofibrosis and leukemia. Haematologica 2003;88:13-8.

    PubMed  Google Scholar 

  11. Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408-17.

    Article  PubMed  CAS  Google Scholar 

  12. Baccarani M, Saglio G, Goldman J, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006;108:1809-20.

    Article  PubMed  CAS  Google Scholar 

  13. Chronic Myelogenous Leukemia. Clinical practice guidelines in oncology. In: Version 2.2009 ed: 2006 National Comprehensive Cancer Network, Inc.

    Google Scholar 

  14. Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer 2009;115:551-60.

    Article  PubMed  CAS  Google Scholar 

  15. le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood 2008;111:1834-9.

    Article  PubMed  Google Scholar 

  16. Hochhaus A, Kantarjian HM, Baccarani M, et al. Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy. Blood 2007;109:2303-9.

    Article  PubMed  CAS  Google Scholar 

  17. Tefferi A, Spivak JL. Polycythemia vera: scientific advances and current practice. Semin Hematol 2005;42:206-20.

    Article  PubMed  CAS  Google Scholar 

  18. Landolfi R, Marchioli R, Kutti J, et al. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-24.

    Article  PubMed  CAS  Google Scholar 

  19. Fruchtman SM, Mack K, Kaplan ME, Peterson P, Berk PD, Wasserman LR. From efficacy to safety: a Polycythemia Vera Study group report on hydroxyurea in patients with polycythemia vera. Semin Hematol 1997;34:17-23.

    PubMed  CAS  Google Scholar 

  20. Tefferi A, Gangat N, Wolanskyj AP. Management of extreme thrombocytosis in otherwise low-risk essential thrombocythemia; does number matter? Blood 2006;108:2493-4.

    Article  PubMed  CAS  Google Scholar 

  21. Harrison CN, Campbell PJ, Buck G, et al. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia. N Engl J Med 2005;353:33-45.

    Article  PubMed  CAS  Google Scholar 

  22. Finazzi G, Ruggeri M, Rodeghiero F, Barbui T. Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial. Br J Haematol 2000;110:577-83.

    Article  PubMed  CAS  Google Scholar 

  23. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 2008;83:491-7.

    Article  PubMed  CAS  Google Scholar 

  24. Lofvenberg E, Wahlin A. Management of polycythaemia vera, essential thrombocythaemia and myelofibrosis with hydroxyurea. Eur J Haematol 1988;41:375-81.

    Article  PubMed  CAS  Google Scholar 

  25. Tefferi A, Jimenez T, Gray LA, Mesa RA, Chen MG. Radiation therapy for symptomatic hepatomegaly in myelofibrosis with myeloid metaplasia. Eur J Haematol 2001;66:37-42.

    Article  PubMed  CAS  Google Scholar 

  26. Steensma DP, Hook CC, Stafford SL, Tefferi A. Low-dose, single-fraction, whole-lung radiotherapy for pulmonary hypertension associated with myelofibrosis with myeloid metaplasia. Br J Haematol 2002;118:813-6.

    Article  PubMed  Google Scholar 

  27. Elliott MA, Chen MG, Silverstein MN, Tefferi A. Splenic irradiation for symptomatic splenomegaly associated with myelofibrosis with myeloid metaplasia. Br J Haematol 1998;103:505-11.

    Article  PubMed  CAS  Google Scholar 

  28. Kroger N, Mesa RA. Choosing between stem cell therapy and drugs in myelofibrosis. Leukemia 2008;22:474-86.

    Article  PubMed  CAS  Google Scholar 

  29. Pesu M, Laurence A, Kishore N, Zwillich SH, Chan G, O’Shea JJ. Therapeutic targeting of Janus kinases. Immunol Rev 2008;223:132-42.

    Article  PubMed  CAS  Google Scholar 

  30. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008;111:1774-80.

    Article  PubMed  CAS  Google Scholar 

  31. Jones D, Kamel-Reid S, Bahler D, et al. Laboratory practice guidelines for detecting and reporting BCR-ABL drug resistance mutations in chronic myelogenous leukemia and acute lymphoblastic leukemia: a report of the Association for Molecular Pathology. J Mol Diagn 2009;11:4-11.

    Article  PubMed  CAS  Google Scholar 

  32. Quintas-Cardama A, Kantarjian H, Manshouri T, et al. Pegylated interferon alfa-2a yields high rates of hematologic and molecular response in patients with advanced essential thrombocythemia and polycythemia vera. J Clin Oncol 2009;27:5418-24.

    Google Scholar 

  33. Tefferi A, Cortes J, Verstovsek S, et al. Lenalidomide therapy in myelofibrosis with myeloid metaplasia. Blood 2006;108:1158-1164.

    Google Scholar 

  34. Millecker L, Lennon P, Verstovsek S, et al. Distinct patterns of cytogenetic and clinical progression in chronic myeloproliferative neoplasms with or without JAK2 or MPL mutations. Cancer Genet Cytogenet 2010;196.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Pharmacy, M. D. Anderson Cancer Center, The University of Texas, Houston, TX, USA

    Starla Sweany

  2. Department of Leukemia, M. D. Anderson Cancer Center, The University of Texas, Houston, TX, USA

    Elias Jabbour

Authors
  1. Starla Sweany
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Elias Jabbour
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Elias Jabbour .

Editor information

Editors and Affiliations

  1. M.D. Anderson Cancer Center, The University of Texas, Holcombe Blvd. 1515 , Houston, 77030, U.S.A.

    Dan Jones

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Humana Press, a part of Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Sweany, S., Jabbour, E. (2010). Treatment of Myeloproliferative Neoplasms. In: Jones, D. (eds) Neoplastic Hematopathology. Contemporary Hematology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-60761-384-8_11

Download citation

  • DOI: https://doi.org/10.1007/978-1-60761-384-8_11

  • Published:

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-60761-383-1

  • Online ISBN: 978-1-60761-384-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation